• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Start-Up Stadium Tuesday Afternoon

Tuesday, June 04, 2024
5B
Start-Up Stadium is designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, strategic partners, and non-dilutive capital at the world’s largest biotechnology partnering event. During the 2024 BIO International Convention select finalists from around the world will share a quick pitch showcasing new technologies and therapeutic solutions to a panel of investor judges, followed by live feedback. This year will also feature evaluation of the presentations from seed-stage company finalists (less than $1M raised) separate from emerging company finalists (more than $1M but less than $10M raised to date). with a winner identified for each category. Past prizes have included 'fast-track' admission review to incubator programs at the Illumina Accelerator and The Innovation Space, as well as complimentary, one-year memberships in the Biotechnology Innovation Organization with access to the cost-savings programs of BIO Business Solutions.
Loading
2:00 PM – 4:00 PM
(PST)
  1. Cha Therapeutics seeks to realize the untapped potential of immune checkpoint inhibitors (ICIs).
    SUS
    • Oncology
  2. The mission of Everfront Biotech is to address unmet medical needs by developing orphan drugs to treat some of the world's deadliest diseases, including high-grade gliomas and pancreatic cancer.
    SUS
    • Oncology
  3. Biotech company with the goal to solve the antimicrobial resistance pandemic for anyone, anything, anywhere.
    SUS
    • Infectious Disease and Vaccines
  4. Matrubials Inc. is developing milk-inspired therapeutics to address infectious diseases.
    SUS
    • Infectious Disease and Vaccines
  5. Merlin has a pre-clinical mRNA-delivered immune activator with strong IP with in-vivo and human epi survival data in both pediatric ($100M PRV) and $2B adult markets.
    SUS
    • Oncology
  6. Oniria Therapeutics aims to revolutionize cancer treatment by bringing to market the first-in-class drug ONR-001, designed for solid and liquid aggressive tumors unresponsive to current treatments, paving the way for novel therapeutic combinations or standalone treatments.
    SUS
    • Oncology
  7. PHIOGEN is a spin-off from Baylor College of Medicine and was born out of innovation from the globally renowned team at TAILOR Labs, one of the US's only bacteriophage therapy centers, now being commercialized to combat the AMR infection crisis.
    SUS
    • Infectious Disease and Vaccines
  8. Synergy Therapeutics Inc. has discovered and developed a novel and disruptive way to potently upregulate p53, the "guardian of the genome", in both wildtype and mutant cancer cells.
    SUS
    • Oncology
  9. Tachmed develops revolutionary, proprietary technologies designed to detect chronic and infectious diseases.
    SUS
    • Diagnostics and Personalized Medicine

 
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS